A new S&P Global Energy study reveals that most future global energy demand growth will come from emerging markets and developing economies (EMDEs), rising over 60% by 2060. This surge challenges ambitious climate targets like limiting warming to 1.5°C, with net-zero emissions before 2100 unlikely globally. While holding temperature rise to 2°C remains possible under aggressive decarbonization, practical limits in electrification and renewable integration, alongside energy security and affordability concerns, mean fossil fuels will still play a significant role. The study emphasizes a complex, regionally differentiated energy transition requiring large investments and balancing economic growth with emissions reduction.
Energy demand growth is the subject, with Pluang market data providing context. As of Sep 17, 2026 18:11 WIB, 21 of 30 Energy-sector US stocks rose. Devon Energy Corp (DVN) traded at USD 48.64 with a 0.41% increase and 74% sell order activity. Cenovus Energy Inc (CVE) fell 0.40% to USD 32.39, with 95% buy orders. Kinder Morgan Inc (KMI) rose 0.39% to USD 30.85, with 69% buy orders. This snapshot shows varied investor interest and trading patterns in energy stocks on Pluang.
U.S. spot Bitcoin ETFs experienced a sharp reversal with $524.8 million in inflows on October 21 followed by $635.6 million in outflows on October 22 and another $137.9 million withdrawn on October 23. Despite these withdrawals, the net inflow for th...
Ethereum prices fell to the $2,350-$2,380 range following large sell-offs by BitMEX co-founder Arthur Hayes, who liquidated Ethereum and DeFi assets ahead of the Federal Reserve's critical policy meeting. This move reflects institutional caution amid...
Stellar Lumens (XLM) was trading at $0.1679 on October 25, slightly below the forecasted target of $0.174 set for October 27. This represents a 1.66% increase expected by the forecast, but the current price is down 1.08% over the past 24 hours. Techn...
The SEC has approved the listing of six triple-leveraged ETFs from Volatility Shares on the Cboe BZX Exchange, including 3x Bitcoin and 3x Ether ETFs. This marks the first US regulatory approval for crypto products with such high leverage. However, t...
Regeneron's Libtayo (cemiplimab) demonstrates a growing overall survival benefit for high-risk cutaneous squamous cell carcinoma (CSCC) patients after nearly four years of follow-up in the Phase 3 C-POST trial. The data reveal a 37% reduction in deat...
